Zurück zu Projekte

16018.2 PFLS-LS

Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

Zusammenfassung

Targeting of the IL-23 Receptor to eliminate auto-reactive lymphocytes in chronic inflammatory diseases

Weitere Texte

Abstract

A novel mechanism of action for the sustainable therapy of human chronic inflammatory diseases, acting|through targeted lysis of disease-driving cell, shall be investigated here. A lead molecule active in human|and non-human primates has been identified and will be developed to enable clinical testing. To support|the preclinical development a bispecific surrogate antibody fragment active in mice will be engineered and|tested in relevant mouse models for chronic inflammatory diseases to study efficacy as well as certain|safety relevant parameters.

Beteiligte

David Urech

Wirtschaftspartner

d.urech@numab.com

Numab AG David Urech Einsiedlerstrasse 34 8820 Wädenswil ZH CH

Burkhard Becher

Kontaktperson

becher@immunology.uzh.ch

Universität Zürich Burkhard Becher Winterthurerstrasse 190 8057 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2014-02-28
Enddatum
2016-12-31
Bewilligte Gesamtkosten
CHF 690580.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%